Pacira Biosciences, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Pacira Biosciences, Inc. on May 4, 2022. The filing primarily serves to announce the Company's financial results for the first quarter ended March 31, 2022, and to report the appointment of a new Chief Operating Officer.
Key Financial Metrics
The filing references an earnings press release (Exhibit 99.1) containing the detailed financial results for the first quarter of 2022. However, the text of this Form 8-K does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. Investors must refer to the attached press release for these figures.
Material Changes and Management Actions
Executive Appointment: On May 4, 2022, Daryl Gaugler was promoted from Senior Vice President, Commercial Operations to Chief Operating Officer, effective immediately. Mr. Gaugler has served the Company since June 2019 and previously spent over 20 years with Quintiles Transnational (now IQVIA).
Compensation Changes: In connection with his promotion, Mr. Gaugler's annual base salary was increased to $485,000. His target bonus remains at 50% of his base salary for 2022.
Severance and Change of Control Provisions:
- Standard Termination: If terminated without cause or for good reason, Mr. Gaugler is entitled to nine months of salary continuation, 12 months of health insurance, and accelerated vesting of equity that would have vested during the nine-month period.
- Change of Control: If terminated without cause or for good reason within 30 days prior to or 12 months following a change of control, he is entitled to 12 months of salary continuation, a bonus equal to 35% of his base salary, 12 months of health insurance, and immediate vesting of all outstanding unvested options and restricted stock units.
Guidance, Outlook, and Risks
The filing text does not contain specific forward-looking guidance, management commentary on future outlook, or a discussion of risks and contingencies beyond the standard legal disclaimers regarding the press release. The document notes that the information in Item 2.02 and Exhibit 99.1 is not deemed "filed" for purposes of Section 18 of the Exchange Act.
Key Facts for Investor Verification
- Review Exhibit 99.1 (Earnings Press Release) for specific Q1 2022 financial metrics (revenue, net income, cash flow) as they are not listed in the 8-K text.
- Verify the impact of the new COO appointment on the Company's commercial strategy and operational execution.
- Note the specific severance obligations and change of control provisions for the new COO, which include significant salary continuation and equity acceleration.
- Confirm the Company's status as a Delaware corporation with common stock trading on the Nasdaq Global Select Market under the symbol PCRX.